Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications

Iva Selke Krulichová, Gisbert W Selke, Uwe Eichler, Veronika Lappe, Brian Godman, Ingrid Schubert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Combined hormonal contraceptives (CHC) exhibit differing risks for cardiovascular and thrombotic events (VTE). A European referral process confirmed higher VTE risks for 3 rd generation gestagens and drospirenone. CHC are now grouped in risk classes (RC) I, II, and III, with RC III having a higher risk than RC I and X (risk not yet known). Marketing authorization holders were obliged to implement pharmacovigilance measures and risk minimization measures including changes of prescribing information. The study assessed whether these activities induced changes in prescription patterns. Methods: German prescription data for 1.1 million women below 20 years of age were used to analyze the effects of interventions and potential influence factors using logistic regression. Descriptive statistics were calculated for prescriptions for 3.3 million women from January 2011 to March 2016. Results: Shares of RC I and RC X recipients rose substantially over the observation period, while RC III recipient share showed a steady decrease. The referral induced a slightly faster decrease in RC III and increase in RC X. The implementation of pharmacovigilance measures manifested no additional effect. Conclusion: The decrease in RC III share already observed before the referral process can be explained with pre-existing discussions around CHC. The effect attributable to the referral was statistically significant, although very small. While evidence for a connection between interventions and prescription change is only indirect, the study shows that routine data are suitable for impact analyses, and monitoring prescribing patterns can be recommended as feedback after regulatory or political interventions. This is being followed up.

LanguageEnglish
Pages697-704
Number of pages8
JournalCurrent Medical Research and Opinion
Volume35
Issue number4
Early online date26 Oct 2018
DOIs
Publication statusPublished - 30 Apr 2019

Fingerprint

Contraceptive Agents
Germany
Prescriptions
Referral and Consultation
Pharmacovigilance
Progestins
Marketing
Logistic Models
Observation

Keywords

  • combined hormonal contraceptives
  • intervention analysis
  • pharmacoepidemiology
  • thromboembolism
  • Germany

Cite this

@article{4246839b04524aa08fbadaeaca85a6a2,
title = "Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications",
abstract = "Objective: Combined hormonal contraceptives (CHC) exhibit differing risks for cardiovascular and thrombotic events (VTE). A European referral process confirmed higher VTE risks for 3 rd generation gestagens and drospirenone. CHC are now grouped in risk classes (RC) I, II, and III, with RC III having a higher risk than RC I and X (risk not yet known). Marketing authorization holders were obliged to implement pharmacovigilance measures and risk minimization measures including changes of prescribing information. The study assessed whether these activities induced changes in prescription patterns. Methods: German prescription data for 1.1 million women below 20 years of age were used to analyze the effects of interventions and potential influence factors using logistic regression. Descriptive statistics were calculated for prescriptions for 3.3 million women from January 2011 to March 2016. Results: Shares of RC I and RC X recipients rose substantially over the observation period, while RC III recipient share showed a steady decrease. The referral induced a slightly faster decrease in RC III and increase in RC X. The implementation of pharmacovigilance measures manifested no additional effect. Conclusion: The decrease in RC III share already observed before the referral process can be explained with pre-existing discussions around CHC. The effect attributable to the referral was statistically significant, although very small. While evidence for a connection between interventions and prescription change is only indirect, the study shows that routine data are suitable for impact analyses, and monitoring prescribing patterns can be recommended as feedback after regulatory or political interventions. This is being followed up.",
keywords = "combined hormonal contraceptives, intervention analysis, pharmacoepidemiology, thromboembolism, Germany",
author = "{Selke Krulichov{\'a}}, Iva and Selke, {Gisbert W} and Uwe Eichler and Veronika Lappe and Brian Godman and Ingrid Schubert",
year = "2019",
month = "4",
day = "30",
doi = "10.1080/03007995.2018.1541317",
language = "English",
volume = "35",
pages = "697--704",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
number = "4",

}

Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications. / Selke Krulichová, Iva; Selke, Gisbert W; Eichler, Uwe; Lappe, Veronika; Godman, Brian; Schubert, Ingrid.

In: Current Medical Research and Opinion, Vol. 35, No. 4, 30.04.2019, p. 697-704.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of EU risk assessment process and administrative regulations for manufacturers of combined hormonal contraceptive prescribing. An analysis of developments in Germany and the implications

AU - Selke Krulichová, Iva

AU - Selke, Gisbert W

AU - Eichler, Uwe

AU - Lappe, Veronika

AU - Godman, Brian

AU - Schubert, Ingrid

PY - 2019/4/30

Y1 - 2019/4/30

N2 - Objective: Combined hormonal contraceptives (CHC) exhibit differing risks for cardiovascular and thrombotic events (VTE). A European referral process confirmed higher VTE risks for 3 rd generation gestagens and drospirenone. CHC are now grouped in risk classes (RC) I, II, and III, with RC III having a higher risk than RC I and X (risk not yet known). Marketing authorization holders were obliged to implement pharmacovigilance measures and risk minimization measures including changes of prescribing information. The study assessed whether these activities induced changes in prescription patterns. Methods: German prescription data for 1.1 million women below 20 years of age were used to analyze the effects of interventions and potential influence factors using logistic regression. Descriptive statistics were calculated for prescriptions for 3.3 million women from January 2011 to March 2016. Results: Shares of RC I and RC X recipients rose substantially over the observation period, while RC III recipient share showed a steady decrease. The referral induced a slightly faster decrease in RC III and increase in RC X. The implementation of pharmacovigilance measures manifested no additional effect. Conclusion: The decrease in RC III share already observed before the referral process can be explained with pre-existing discussions around CHC. The effect attributable to the referral was statistically significant, although very small. While evidence for a connection between interventions and prescription change is only indirect, the study shows that routine data are suitable for impact analyses, and monitoring prescribing patterns can be recommended as feedback after regulatory or political interventions. This is being followed up.

AB - Objective: Combined hormonal contraceptives (CHC) exhibit differing risks for cardiovascular and thrombotic events (VTE). A European referral process confirmed higher VTE risks for 3 rd generation gestagens and drospirenone. CHC are now grouped in risk classes (RC) I, II, and III, with RC III having a higher risk than RC I and X (risk not yet known). Marketing authorization holders were obliged to implement pharmacovigilance measures and risk minimization measures including changes of prescribing information. The study assessed whether these activities induced changes in prescription patterns. Methods: German prescription data for 1.1 million women below 20 years of age were used to analyze the effects of interventions and potential influence factors using logistic regression. Descriptive statistics were calculated for prescriptions for 3.3 million women from January 2011 to March 2016. Results: Shares of RC I and RC X recipients rose substantially over the observation period, while RC III recipient share showed a steady decrease. The referral induced a slightly faster decrease in RC III and increase in RC X. The implementation of pharmacovigilance measures manifested no additional effect. Conclusion: The decrease in RC III share already observed before the referral process can be explained with pre-existing discussions around CHC. The effect attributable to the referral was statistically significant, although very small. While evidence for a connection between interventions and prescription change is only indirect, the study shows that routine data are suitable for impact analyses, and monitoring prescribing patterns can be recommended as feedback after regulatory or political interventions. This is being followed up.

KW - combined hormonal contraceptives

KW - intervention analysis

KW - pharmacoepidemiology

KW - thromboembolism

KW - Germany

U2 - 10.1080/03007995.2018.1541317

DO - 10.1080/03007995.2018.1541317

M3 - Article

VL - 35

SP - 697

EP - 704

JO - Current Medical Research and Opinion

T2 - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 4

ER -